DexCom, Inc. DXCM NASDAQ

DexCom, Inc. (DXCM) reported total assets of $6.34B and total liabilities of $3.59B for fiscal year 2025, resulting in total equity of $2.75B.

The company held $2B in cash and short-term investments. Total debt stood at $1.39B, with net debt of $472M. The Debt-to-Equity (D/E) ratio was 0.51 (moderate).

Current ratio is 1.88, indicating strong short-term liquidity.

Criteria supported by this page:

• HEALTH (83/100, Pass) — Debt-to-Equity of 0.51, current ratio of 1.88 — balance sheet is strong
• MOAT (71/100) — Total assets $6.34B and equity $2.75B support the company's competitive scale
• VALUE (69/100) — Debt-to-Equity 0.51 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 82/100 with 7/7 criteria passed.

ABT

Abbott Laboratories

$101.07

+0.38%

MDT

Medtronic plc

$88.12

+0.14%

BSX

Boston Scientific Corporation

$63.82

+1.01%

EW

Edwards Lifesciences Corporation

$78.20

+0.10%

ZBH

Zimmer Biomet Holdings, Inc.

$96.52

+1.24%

PODD

Insulet Corporation

$201.49

+1.86%

PEN

Penumbra, Inc.

$332.17

+0.21%

SWAV

ShockWave Medical, Inc.

$334.75

-0.02%